PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-409.95%
Working capital is shrinking yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage if sales remain robust.
-293.36%
AR shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage in working capital if sales do not drop.
-413.10%
Inventory shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a working capital edge if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
279.96%
Under 50% of Drug Manufacturers - Specialty & Generic median of 46.37% if negative or far above if positive. Jim Chanos would sense potential red flags or large tie-ups in these rarely monitored accounts.
14552.31%
A moderate rise while Drug Manufacturers - Specialty & Generic median is negative at -18.65%. Peter Lynch might see peers cleaning up intangible or one-time items more aggressively.
-122.31%
Negative CFO growth while Drug Manufacturers - Specialty & Generic median is 85.85%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16698.32%
Under 50% of Drug Manufacturers - Specialty & Generic median of 98.89% if negative or well above if positive. Jim Chanos would suspect a large mismatch or potential waste if outflows are too high vs. peers.
11462.18%
Under 50% of Drug Manufacturers - Specialty & Generic median of 92.99% if negative or well above if positive. Jim Chanos sees potential overspending or major liquidity drain overshadowing typical sector levels.
67.84%
We repay slightly more while Drug Manufacturers - Specialty & Generic median is negative at -48.35%. Peter Lynch would see a relative advantage in lowering debt obligations vs. peers adding leverage.
-23.99%
We reduce issuance yoy while Drug Manufacturers - Specialty & Generic median is -37.35%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.